Partnerships

GlaxoSmithKline Immuno-Oncology Financial Collaboration
Our immuno-oncology financial collaboration with GlaxoSmithKline (GSK) is focused upon the development and commercialization of Anaptys-generated checkpoint antagonist antibodies to PD-1 and TIM-3. The exclusively licensed products being advanced by GSK under this partnership include Jemperli™ (dostarlimab) and cobolimab in second line NSCLC.
Significant potential royalties from GSK immuno-oncology financial collaboration

Royalties

(Anti-PD-1 antagonist)

8% royalties on annual net sales <$1B**

  • 12-25% royalties on annual net sales ≥ $1B
Cobolimab(Anti-TIM-3 antagonist)
  • show in combination with Jemperli
  • 4-8% royalties on annual net sales (Cobolimab portion)
  • 8-25% royalties on annual net sales (Jemperli portion)

Remaining Milestones

(Anti-PD-1 antagonist)

$15mm regulatory
$90MM commercial on annual net sales <$1B**

  • $75mm commercial on annual net sales ≥ $1B
Cobolimab(Anti-TIM-3 antagonist)
  • $5MM clinical development
  • $90MM regulatory
  • $165MM commercial

  • $250mm Jemperli Capped Non-Recourse Monetization
  • 2021 transaction in exchange for selected** Jemperli receivables until Sagard paid back one of the following capped returns:
  • $312.5MM (125%) by end 2026, or
  • $337.5MM (135%) by end 2027, or
  • $412.5MM (165%) if after 2027